Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 7/20 | 0.73 |
| ▸ | GSK3B | P49841 | 6/20 | 0.73 |
| ▸ | PIM1 | P11309 | 3/20 | 0.73 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.67 |
| ▸ | CLK4 | Q9HAZ1 | 5/20 | 0.67 |
| ▸ | STK17A | Q9UEE5 | 3/20 | 0.67 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.64 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.64 |
| ▸ | AURKA | O14965 | 4/20 | 0.64 |
| ▸ | DAPK3 | O43293 | 4/20 | 0.64 |
| ▸ | GSK3A | P49840 | 4/20 | 0.64 |
| ▸ | CLK2 | P49760 | 4/20 | 0.64 |
| ▸ | JAK2 | O60674 | 4/20 | 0.64 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.64 |
| ▸ | PRKACA | P17612 | 3/20 | 0.64 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.64 |
| ▸ | KDR | P35968 | 2/20 | 0.64 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.64 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.64 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3668427 | 0.84 | ROCK2 (1.00) | ROCK2GSK3BPIM1DYRK1ACLK4 | |
| SCHEMBL3634807 | 0.83 | ROCK2 (0.71) | ROCK2GSK3BPIM1DYRK1ACLK4 | |
| SCHEMBL3637581 | 0.81 | ROCK2 (0.66) | ROCK2GSK3BPIM1DYRK1ACLK4 | |
| SCHEMBL3666769 | 0.80 | ROCK2 (1.00) | ROCK2GSK3BPIM1DYRK1ACLK4 | |
| SCHEMBL3670364 | 0.80 | ROCK2 (0.67) | ROCK2GSK3BPIM1DYRK1ACLK4 | |
| SCHEMBL3667340 | 0.80 | ROCK2 (0.70) | ROCK2GSK3BPIM1DYRK1ACLK4 | |
| SCHEMBL4287675 | 0.80 | ROCK2 (0.82) | ROCK2GSK3BPIM1DYRK1ACLK4 | |
| SCHEMBL13902053 | 0.80 | ROCK2 (0.70) | ROCK2GSK3BPIM1DYRK1ACLK4 | |
| SCHEMBL3670619 | 0.79 | ROCK2 (0.73) | ROCK2GSK3BPIM1DYRK1ACLK4 | |
| SCHEMBL4291905 | 0.79 | ROCK2 (0.68) | ROCK2GSK3BPIM1DYRK1ACLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9163007-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20140343066-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-11-20 | — | — | US | disclosed |
| US-8648069-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2014-02-11 | — | — | US | disclosed |
| EP-2167491-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | Abbott Laboratories (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
| WO-2009011850-A2 | NOVEL THERAPEUTIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009011850-A2 | NOVEL THERAPEUTIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2009-01-22 | — | — | WO | disclosed |
| WO-2008154241-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343066-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | GSK3B, GSK3A, PIM3 | ROCK2 48/4885GSK3B 1/4885PIM1 11/4885 |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | GSK3B, GSK3A, PIM3 | ROCK2 48/4885GSK3B 1/4885PIM1 11/4885 |
| US-20090069288-A1 | Novel therapeutic compounds | MAP3K20, RPS6KB1, MAP3K1 | ROCK2 858/4885GSK3B 1142/4885PIM1 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.